A Phase 1/2 Study of IPH6501, a Novel Immunotherapy, in People With Non-Hodgkin Lymphoma


Full Title

A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients with Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma


Researchers want to find the best dose of IPH6501 that can be used safely in people with non-Hodgkin lymphoma (NHL). The people in this study have NHL that returned or keeps growing after treatment and makes a protein called CD20. The types of lymphoma eligible for this study include:

  • Diffuse large B cell lymphoma (DLBCL)
  • High-grade B-cell lymphoma
  • Primary mediastinal large B-cell lymphoma
  • Follicular lymphoma (FL)
  • Mantle cell lymphoma (MCL)
  • Marginal zone lymphoma (MZL)

IPH6501 helps immune system cells find and kill cancer cells. It is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have DLBCL, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, FL, MCL, or MZL that returned or keeps growing after treatment.
  • Have NHL that makes the CD20 protein.
  • Have recovered from any serious side effects of prior therapies before getting IPH6501.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Lorenzo Falchi’s office at 646-608-3705.




Phase I/II (phases 1 and 2 combined)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID